Featured Publications
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
Shinoda K, Li R, Rezk A, Mexhitaj I, Patterson K, Kakara M, Zuroff L, Bennett J, von Büdingen H, Carruthers R, Edwards K, Fallis R, Giacomini P, Greenberg B, Hafler D, Ionete C, Kaunzner U, Lock C, Longbrake E, Pardo G, Piehl F, Weber M, Ziemssen T, Jacobs D, Gelfand J, Cross A, Cameron B, Musch B, Winger R, Jia X, Harp C, Herman A, Bar-Or A. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2207291120. PMID: 36634138, PMCID: PMC9934304, DOI: 10.1073/pnas.2207291120.Peer-Reviewed Original ResearchConceptsEarly disease activityDisease activityCD8 T cellsT cellsCD20 therapyPeripheral blood mononuclear cellsCellular immune profilesNew disease activityMS disease activityT cell poolMultiple sclerosis patientsAnti-inflammatory profileBlood mononuclear cellsTreatment-associated changesMultiparametric flow cytometryCentral nervous systemFurther dosingRepeat infusionsImmune profileMS patientsSclerosis patientsValidation cohortMononuclear cellsRelapse developmentImmune cascade
2024
Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments
Lambert C, Hussain T, Peters J, Longbrake E. Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments. Multiple Sclerosis And Related Disorders 2024, 94: 106236. PMID: 39755026, PMCID: PMC11869388, DOI: 10.1016/j.msard.2024.106236.Peer-Reviewed Original ResearchConceptsCharlson Comorbidity IndexAnti-CD20 medicationsDisease-modifying treatmentsDMT useS1P modulatorsImmunomodulatory treatmentImmune cellsSevere infectionsMultiple sclerosisLong-term immunomodulatory treatmentReal-life practice patternsTreatment durationInfection rateSelection of patientsClinical selection of patientsDeplete immune cellsObservational cohort studyBody mass indexSevere infection rateAnalyzed medical recordsIncreased infection riskInfection riskDisease modifying therapiesMultiple sclerosis patientsImmune subsets
2022
Risks of Minor and Severe Infections in Multiple Sclerosis Patients Treated with Long-term B-cell Depletion (P13-4.011)
Peters J, Longbrake E. Risks of Minor and Severe Infections in Multiple Sclerosis Patients Treated with Long-term B-cell Depletion (P13-4.011). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1270.Peer-Reviewed Original ResearchLong-term B-cell depletionB-cell depletionMultiple sclerosis patientsSclerosis patientsSevere infectionsPatientsInfection
2021
Ocrelizumab impacts IgA coating of immunomodulatory gut bacteria in multiple sclerosis patients (2785)
Janda G, Cohen I, Ruff W, Longbrake E. Ocrelizumab impacts IgA coating of immunomodulatory gut bacteria in multiple sclerosis patients (2785). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.2785.Peer-Reviewed Original Research
2015
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
Longbrake E, Ramsbottom M, Cantoni C, Ghezzi L, Cross A, Piccio L. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Multiple Sclerosis Journal 2015, 22: 1061-1070. PMID: 26459150, PMCID: PMC4829494, DOI: 10.1177/1352458515608961.Peer-Reviewed Original ResearchConceptsDMF-treated patientsMemory T cellsMultiple sclerosis patientsT cellsMS patientsDendritic cellsSclerosis patientsEffector memory T cellsUntreated MS patientsMyeloid dendritic cellsAbsolute lymphocyte countPlasmacytoid dendritic cellsNatural killer cellsNaïve T cellsMechanism of actionLymphocyte countLymphopenic patientsRegulatory cellsKiller cellsPeripheral bloodImmune cellsHealthy controlsPatientsB cellsFlow cytometry
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply